Corcept Therapeutics Inc

CORTHealthcare·Biotechnology·USA·Mid·NASD·Nov 11 • 2:20 PM ET

74.14+0.79 (1.08%)

2026-11-11 20:21 CET

Market cap

8,027.64 USD m

Revenue, TTM

963.65 USD m

Net income, TTM

159.33 USD m

Free cash flow, TTM

194.62 USD m

EPS diluted, TTM

1.27

P/E

58.51

Compare

Price

CORT against its 20, 50 and 200-day averages

2050200beat

41.3% under the 52-week high of 126.38 on 25 Aug 2026. 52-week low 28.66 on 19 Feb 2026. Last 15 sessions, 64.1% high to low

Profile

CORT

52-week range, 47% of the way up

28.66126.38

Corcept Therapeutics, Inc. engages in the business of discovering and developing pharmaceutical products and medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol. The company was founded by David B. Singer and Joseph K. Belanoff on May 13, 1998 and is headquartered in Redwood City, CA.

Index	RUI
Employees	730
IPO	Apr 14, 2004
Beta	0.58
ATR, 14d	5.58
Rel volume	0.59
Short float	9.41%
Insider own	11.40%
Inst own	74.54%

Snapshot

6 groups

Valuation

Index	RUI
Market Cap	8.11B
Enterprise Value	7.75B
Income	159.33M
Sales	963.65M
Book/sh	7.62
Cash/sh	3.39
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	0.00%
Employees	730
IPO	Apr 14, 2004

Ratios

P/E	58.51
Forward P/E	15.41
PEG	0.14
P/S	8.42
P/B	9.73
P/C	21.89
P/FCF	41.69
EV/EBITDA	68.08
EV/Sales	8.04
Quick Ratio	2.90
Current Ratio	2.97
Debt/Eq	0.01
LT Debt/Eq	0.01
Option/Short	Yes / Yes

Earnings

EPS (ttm)	1.27
EPS next Y	4.81
EPS next Q	1.12
EPS this Y	175.85%
EPS next Y	112.64%
EPS next 5Y	110.90%
EPS past 3/5Y	-2.15% -0.84%
Sales past 3/5Y	23.74% 16.56%
EPS Y/Y TTM	48.80%
Sales Y/Y TTM	30.02%
EPS Q/Q	523.32%
Sales Q/Q	63.97%
Earnings	Nov 03 AMC
EPS/Sales Surpr.	20.24% 0.40%

Ownership

Insider Own	11.40%
Insider Trans	-6.31%
Inst Own	74.54%
Inst Trans	-1.12%
ROA	17.15%
ROE	21.74%
ROIC	18.95%
Gross Margin	98.54%
Oper. Margin	11.51%
Profit Margin	16.53%
SMA20	-17.54%
SMA50	-29.54%
SMA200	-2.72%
Trades	-

Technical

Shs Outstand	109.36M
Shs Float	96.97M
Short Float	9.41%
Short Ratio	7.47
Short Interest	9.13M
52W High	126.38 -41.34%
52W Low	28.66 158.69%
Volatility	9.77% 6.75%
ATR (14)	5.58
RSI (14)	26.50
Beta	0.58
Rel Volume	0.59
Avg Volume	1.22M
Volume	550,669

Performance

Perf Week	-6.41%
Perf Month	-37.06%
Perf Quarter	-32.91%
Perf Half Y	29.89%
Perf YTD	113.05%
Perf Year	-6.16%
Perf 3Y	196.20%
Perf 5Y	228.78%
Perf 10Y	662.76%
Recom	1.86
Target Price	142.60
Prev Close	73.35
Price	74.14
Change %	1.08%

Analyst ratings

latest 10 of 20

Date	Action	Analyst	Rating change	Target	Implied
Aug 18, 2026	Resumed	TTruist	Buy	$164	+121.2%
Jul 27, 2026	Downgrade	WWolfe Research	Peer Perform → Underperform	$50	-32.6%
May 13, 2026	Upgrade	UUBS	Neutral → Buy	$72	-2.9%
Mar 26, 2026	Upgrade	WWolfe Research	Underperform → Peer Perform
Dec 31, 2025	Downgrade	WWolfe Research	Peer Perform → Underperform	$30	-59.5%
Dec 16, 2025	Initiated	UUBS	Neutral
Nov 18, 2025	Initiated	WWolfe Research	Peer Perform
Nov 06, 2023	Upgrade	TTruist	Hold → Buy	$29 → $38	-48.7%
Apr 11, 2023	Initiated	SSVB Securities	Market Perform	$25	-66.3%
Apr 04, 2023	Initiated	PPiper Sandler	Overweight	$27	-63.6%

Date

Action

Analyst

Rating change

Target

Implied

Aug 18, 2026

Resumed

TTruist

Buy

$164

+121.2%

Jul 27, 2026

Downgrade

WWolfe Research

Peer Perform → Underperform

$50

-32.6%

May 13, 2026

Upgrade

UUBS

Neutral → Buy

$72

-2.9%

Mar 26, 2026

Upgrade

WWolfe Research

Underperform → Peer Perform

Dec 31, 2025

Downgrade

WWolfe Research

Peer Perform → Underperform

$30

-59.5%

Dec 16, 2025

Initiated

UUBS

Neutral

Nov 18, 2025

Initiated

WWolfe Research

Peer Perform

Nov 06, 2023

Upgrade

TTruist

Hold → Buy

$29 → $38

-48.7%

Apr 11, 2023

Initiated

SSVB Securities

Market Perform

$25

-66.3%

Apr 04, 2023

Initiated

PPiper Sandler

Overweight

$27

-63.6%

Peers

Mkt cap

Ticker	Company	Mkt cap
ASND	Ascendis Pharma A/S	16.85B
XERS	Xeris Biopharma Holdings Inc	2.98B
NBIX	Neurocrine Biosciences Inc	17.52B
BBIO	BridgeBio Pharma Inc	15.43B
RYTM	Rhythm Pharmaceuticals Inc	7.96B
ACAD	Acadia Pharmaceuticals Inc	3.17B
EXEL	Exelixis Inc	17.10B
JAZZ	Jazz Pharmaceuticals plc	15.82B
HRMY	Harmony Biosciences Holdings Inc	2.01B
SUPN	Supernus Inc	6.14B

Ticker

Company

Mkt cap

ASND

Ascendis Pharma A/S

16.85B

XERS

Xeris Biopharma Holdings Inc

2.98B

NBIX

Neurocrine Biosciences Inc

17.52B

BBIO

BridgeBio Pharma Inc

15.43B

RYTM

Rhythm Pharmaceuticals Inc

7.96B

ACAD

Acadia Pharmaceuticals Inc

3.17B

EXEL

Exelixis Inc

17.10B

JAZZ

Jazz Pharmaceuticals plc

15.82B

HRMY

Harmony Biosciences Holdings Inc

2.01B

SUPN

Supernus Inc

6.14B

Insider trading

latest 14 of 100

Insider	Relationship	Date	Transaction	Cost	Shares	Value	Total held	Form
DANIEL SWISHER JR.	Director	Nov 10 '26	Proposed Sale	75.03	1,500	112,538		Nov 10 04:26 PM
Maduck Sean		Nov 03 '26	Option Exercise	8.27	13,159	108,825	23,097	Nov 04 07:26 PM
Maduck Sean		Nov 02 '26	Option Exercise	8.27	11,841	97,925	21,779	Nov 04 07:26 PM
Maduck Sean		Nov 03 '26	Sale	82.25	13,159	1,082,277	9,938	Nov 04 07:26 PM
Maduck Sean		Nov 02 '26	Sale	81.42	11,841	964,074	9,938	Nov 04 07:26 PM
Vieira Roberto Wandenkolk	President, Oncology	Nov 02 '26	Option Exercise	21.63	8,333	180,243	12,279	Nov 04 07:20 PM
Vieira Roberto Wandenkolk	President, Oncology	Nov 02 '26	Sale	80.89	8,333	674,069	3,946	Nov 04 07:20 PM
WILSON JAMES N	Director	Oct 15 '26	Sale	114.81	10,000	1,148,083	1,054,543	Oct 16 06:24 PM
Vieira Roberto Wandenkolk	President, Oncology	Oct 02 '26	Option Exercise	21.63	8,333	180,243	12,279	Oct 05 07:58 PM
Vieira Roberto Wandenkolk	President, Oncology	Oct 02 '26	Sale	116.10	8,333	967,448	3,946	Oct 05 07:58 PM
Lyon Joseph Douglas	See Remarks	Oct 02 '26	Option Exercise	17.18	9,190	157,864	14,873	Oct 05 07:54 PM
Lyon Joseph Douglas	See Remarks	Oct 01 '26	Option Exercise	13.56	810	10,984	6,493	Oct 05 07:54 PM
Lyon Joseph Douglas	See Remarks	Oct 02 '26	Sale	116.13	9,190	1,067,258	5,683	Oct 05 07:54 PM
Lyon Joseph Douglas	See Remarks	Oct 01 '26	Sale	115.40	810	93,473	5,683	Oct 05 07:54 PM

Held by

AUM

Ticker	Company	AUM
VTI	Vanguard Morningstar Total Stock Market ETF	AUM: 687.42B
IJH	iShares Core S&P Mid-Cap ETF	AUM: 124.48B
VB	Vanguard Morningstar Small-Cap ETF	AUM: 79.59B
VBK	Vanguard Morningstar Small-Cap Growth ETF	AUM: 22.34B
VXF	Vanguard Extended Market Index ETF	AUM: 30.47B
FBT	First Trust NYSE Arca Biotechnology Index Fund	AUM: 3.03B
MDY	State Street SPDR S&P MIDCAP 400 ETF Trust	AUM: 26.22B
IJK	iShares S&P Mid-Cap 400 Growth ETF	AUM: 10.46B
IWP	iShares Russell Mid-Cap Growth ETF	AUM: 18.09B
SPMD	State Street SPDR Portfolio S&P 400TM Mid Cap ETF	AUM: 18.90B

Ticker

Company

AUM

VTI

Vanguard Morningstar Total Stock Market ETF

AUM: 687.42B

IJH

iShares Core S&P Mid-Cap ETF

AUM: 124.48B

Vanguard Morningstar Small-Cap ETF

AUM: 79.59B

VBK

Vanguard Morningstar Small-Cap Growth ETF

AUM: 22.34B

VXF

Vanguard Extended Market Index ETF

AUM: 30.47B

FBT

First Trust NYSE Arca Biotechnology Index Fund

AUM: 3.03B

MDY

State Street SPDR S&P MIDCAP 400 ETF Trust

AUM: 26.22B

IJK

iShares S&P Mid-Cap 400 Growth ETF

AUM: 10.46B

IWP

iShares Russell Mid-Cap Growth ETF

AUM: 18.09B

SPMD

State Street SPDR Portfolio S&P 400TM Mid Cap ETF

AUM: 18.90B

News

latest 14 of 200

Nov-03-26 07:25PMCorcept's Breakout Quarter Collides With A Static Guide And A Stock Near Its Lows (Earnings Whispers)
05:20PMCorcept Therapeutics falls on guidance despite earnings beat (Investing.com)
04:31PMCorcept: Q3 Earnings Snapshot (Associated Press)
03:05PMCorcept Therapeutics Announces Third Quarter Financial Results and Provides Corporate Update (Business Wire)
Oct-27-26 08:36PMCorcept Must Prove Its Lifioly Ramp Can Support A $1.1 Billion Guide (Earnings Whispers)
04:05PMCorcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call (Business Wire)
Oct-26-26 08:00AMCorcept Reports Positive Results from Phase 2 BELLA Trial of Lifyorli Combined with Nab-Paclitaxel and Bevacizumab in Patients with Platinum-Resistant Ovarian Cancer (Business Wire)
Oct-23-26 12:44PMGenmab stock surges 9% following positive phase 3 ovarian cancer trial results (Investing.com) -20.13%
Oct-20-26 04:00PM2026 ADA/EASD Consensus Report Recommends Screening for Hypercortisolism in Patients with Difficult-to-Control Type 2 Diabetes (Business Wire)
Oct-15-26 02:14PMWhy Healthcare Stocks Are Hot When the AI Trade Runs Cold (Barrons.com)
Oct-06-26 04:43PMCorcept, IBD Stock Of The Day, Setting Up Amid Booming Earnings Growth (Investor's Business Daily)
Sep-23-26 08:00AMCorcept Announces Planned Leadership Transition (Business Wire)
Sep-18-26 08:00AMCorcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli (Relacorilant) (Business Wire)
Sep-04-26 07:42PMBE, P, ILMN Join S&P 500; LNG Misses Out Bloom Energy Stock Gains While Cheniere Energy Slips (Stocktwits)

Key figures

Revenue, TTM	963.65
Net income, TTM	159.33
EPS diluted, TTM	1.27
EBIT, TTM	110.91
Free cash flow, TTM	194.62
Gross margin	98.54%
Operating margin	11.51%
Net margin	16.53%
Market cap	8,027.64
P/E	58.51
Sales Y/Y, TTM	30.02%

USD millions. TTM from the statement feed.

Quarterly earnings

actual against estimate

Period	Reported	EPS act	EPS est	EPS rep	Sales act	Sales est	Analysts
2026Q3	2026-11-03	1.010	0.840	1.010	340.47	339.13	5
2026Q2	2026-07-29	0.360	0.024	0.356	256.15	221.15	5
2026Q1	2026-04-30	-0.300	-0.110	-0.299	164.9	185.27	5
2025Q4	2026-02-24	0.200	0.330	0.199	202.13	256.88	5
2025Q3	2025-11-04	0.160	0.164	0.162	207.64	223.16	4
2025Q2	2025-07-31	0.290	0.188	0.287	194.43	199.39	4
2025Q1	2025-05-05	0.170	0.143	0.169	157.21	177.93	4
2024Q4	2025-02-26	0.260	0.426	0.257	181.89	198.74	4
2024Q3	2024-10-30	0.410	0.282	0.411	182.55	171.97	5
2024Q2	2024-07-29	0.320	0.230	0.316	163.8	155.14	5
2024Q1	2024-05-01	0.250	0.220	0.250	146.81	141.19	5
2023Q4	2024-02-15	0.280	0.258	0.281	135.41	129.27	5
2023Q3	2023-11-01	0.280	0.218	0.281	123.6	119.71	6
2023Q2	2023-08-02	0.250	0.150	0.250	117.72	109.6	6
2023Q1	2023-05-03	0.140	0.199	0.137	105.65	104.89	7
2022Q4	2023-02-28	0.140	0.240	0.142	103.06	105.08	5

Annual earnings

Period	EPS act	EPS est	EPS rep	Sales act	Sales est
2019FY	0.770	0.803	0.768	306.49	306.26
2020FY	0.850	0.840	0.854	353.9	358.48
2021FY	0.890	0.893	0.893	365.98	367.75
2022FY	0.870	0.955	0.873	401.86	403.88
2023FY	0.940	0.922	0.944	482.38	476.28
2024FY	1.230	1.408	1.231	675.04	692.67
2025FY	0.820	0.956	0.820	761.41	816.17
2026FY	-	2.262	-	-	1,158
2027FY	-	4.810	-	-	1,703
2028FY	-	7.693	-	-	2,268
2029FY	-	9.603	-	-	2,654
2030FY	-	11.950	-	-	3,094

Estimate revisions

last 14 periods

Period	Type	Date	Estimates	Up	Down	Mean	Low	High
2026Q4	S	2026-11-04	4	2	1	396.63	371.11	436.8
2026Q4	S	2026-11-03	4	0	0	388.75	378.2	402.99
2026Q4	S	2026-11-01	4	0	1	380.78	371.11	387
2026Q4	S	2026-10-30	5	0	1	367.42	314	387
2026Q4	S	2026-10-23	5	0	0	373.8	314	402.99
2026Q4	S	2026-10-22	5	0	0	373.8	314	402.99
2026Q4	S	2026-10-14	5	0	0	373.8	314	402.99
2026Q4	S	2026-10-13	5	0	0	373.8	314	402.99
2026Q4	S	2026-10-07	5	3	0	373.81	314	402.99
2026Q4	S	2026-09-17	5	4	0	373.81	314	402.99
2026Q4	S	2026-08-17	5	4	0	373.81	314	403
2026Q4	S	2026-08-11	4	4	0	370.51	314	403
2026Q4	S	2026-08-07	4	4	0	370.5	314	403
2026Q4	S	2026-07-30	5	4	0	365.92	314	403

Estimate history

Period	2017	2018	2019	2020	2021	2022	2023	2024	2025	TTM
EPS, annual	1.037	0.595	0.768	0.854	0.893	0.873	0.944	1.231	0.818	1.2671
EPS, quarterly	0.411	0.257	0.169	0.287	0.162	0.199	-0.299	0.356	1.01
Period	Q3 '24	Q4 '24	Q1 '25	Q2 '25	Q3 '25	Q4 '25	Q1 '26	Q2 '26	Q3 '26
Sales, annual	159.201	251.247	306.486	353.874	365.978	401.858	482.375	675.04	761.407	963.65
Period	2017	2018	2019	2020	2021	2022	2023	2024	2025	TTM
Sales, quarterly	182.546	181.89	157.214	194.43	207.638	202.125	164.903	256.147	340.472
Period	Q3 '24	Q4 '24	Q1 '25	Q2 '25	Q3 '25	Q4 '25	Q1 '26	Q2 '26	Q3 '26
Shares, annual	114.717	115.031	114.549	116.735	105.94	107.835	103.405	105.113	105.966	109.365
Period	2017	2018	2019	2020	2021	2022	2023	2024	2025	MRQ
Shares, quarterly	104.703	105.113	105.984	105.288	105.124	105.966	107.328	107.921	109.365
Period	Q3 '24	Q4 '24	Q1 '25	Q2 '25	Q3 '25	Q4 '25	Q1 '26	Q2 '26	Q3 '26

Income statement, annual

Currency USD, millions
Metric	TTM	2025FY	2024FY	2023FY	2022FY	2021FY	2020FY	2019FY	2018FY
Total Revenue	963.65	761.41	675.04	482.38	401.86	365.98	353.87	306.49	251.25
Cost of Goods Sold Incl. D&A	14.10	12.98	10.88	6.48	5.38	5.28	5.58	5.50	5.21
Gross Profit	949.55	748.43	664.16	475.89	396.47	360.70	348.29	300.98	246.03
Selling, General and Administrative Excl. Other	838.64	703.63	527.21	368.61	283.84	236.22	220.09	189.38	156.54
Research and Development	241.72	254.91	246.89	184.35	130.99	113.86	114.76	89.02	75.25
Other Operating Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Income	110.91	44.80	136.95	107.28	112.63	124.48	128.20	111.61	89.50
Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Unusual Expense	0.00	0.00	0.00	0.00	0.00	-	-	-	-
Net Income Before Taxes	131.43	66.46	161.49	124.56	116.19	125.01	131.60	116.68	92.15
Income Taxes	-30.86	-33.19	20.28	18.42	14.77	12.49	25.59	22.50	16.74
Consolidated Net Income	159.33	98.17	139.73	105.50	101.29	112.51	106.01	94.18	75.41
Net Income From Continuing Operations	159.33	98.17	139.73	105.50	101.29	112.51	106.01	94.18	75.41
Net Income	159.33	98.17	139.73	105.50	101.29	112.51	106.01	94.18	75.41
EPS (Recurring)	1.29	0.82	1.23	0.94	0.87	0.89	0.85	0.77	0.60
EPS (Basic, Before Extraordinaries)	1.50	0.95	1.35	1.02	0.95	0.97	0.92	0.82	0.65
EPS (Diluted)	1.27	0.82	1.23	0.94	0.87	0.89	0.85	0.77	0.60
EBITDA	113.88	46.69	138.29	108.32	115.60	127.54	130.44	113.78	89.73
Non-Operating Income (Expense)	20.52	21.67	24.54	17.27	3.56	0.53	3.40	5.07	2.66
Other After Tax Adjustments	-2.96	-1.48	-1.48	-0.64	-0.13	0.00	0.00	0.00	0.00
Stock Option Compensation Expense	81.98	67.14	48.73	38.83	33.75	31.51	24.66	21.40	18.76
Price To Earnings Ratio	57.89	57.89	40.07	40.13	20.44	22.11	30.65	15.73	22.42
Price To Sales Ratio	14.73	5.48	8.47	7.52	5.86	6.81	9.18	4.84	6.74
Gross Margin	98.54	98.30	98.39	98.66	98.66	98.56	98.42	98.20	97.92
Operating Margin	11.51	5.88	20.29	22.24	28.03	34.01	36.23	36.41	35.62
Net Margin	16.53	12.89	20.70	21.87	25.20	30.74	29.96	30.73	30.01
Shares Outstanding	109.36	105.97	105.11	103.41	107.83	105.94	116.73	114.55	115.03
Market Capitalization	8,027.64	8,027.64	5,279.61	3,348.07	2,186.37	2,286.11	3,039.09	1,382.80	1,542.71

Income statement, quarterly

Currency USD, millions
Metric	2026Q3	2026Q2	2026Q1	2025Q4	2025Q3	2025Q2	2025Q1	2024Q4
Total Revenue	340.47	256.15	164.90	202.12	207.64	194.43	157.21	181.89
Cost of Goods Sold Incl. D&A	4.61	4.06	2.88	2.54	4.60	3.43	2.40	2.96
Gross Profit	335.86	252.09	162.02	199.58	203.04	191.00	154.81	178.93
Selling, General and Administrative Excl. Other	221.14	210.79	211.62	195.09	192.82	164.32	151.40	153.67
Research and Development	56.71	53.89	66.27	64.86	68.85	60.47	60.73	70.30
Other Operating Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Income	114.72	41.30	-49.60	4.49	10.22	26.68	3.42	25.26
Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Unusual Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Income Before Taxes	120.31	45.93	-44.72	9.91	15.24	31.69	9.62	31.96
Income Taxes	-6.47	2.94	-12.95	-14.38	-4.42	-3.46	-10.93	1.21
Consolidated Net Income	124.49	42.14	-31.20	23.90	19.36	34.61	20.29	30.39
Net Income From Continuing Operations	124.49	42.14	-31.20	23.90	19.36	34.61	20.29	30.39
Net Income	124.49	42.14	-31.20	23.90	19.36	34.61	20.29	30.39
EPS (Recurring)	1.01	0.36	-0.30	0.20	0.16	0.29	0.17	0.26
EPS (Basic, Before Extraordinaries)	1.17	0.40	-0.30	0.23	0.19	0.33	0.19	0.29
EPS (Diluted)	1.01	0.36	-0.30	0.20	0.16	0.29	0.17	0.26
EBITDA	115.75	42.16	-49.00	4.97	10.70	27.14	3.88	25.72
Non-Operating Income (Expense)	5.58	4.63	4.89	5.42	5.02	5.02	6.20	6.70
Other After Tax Adjustments	-2.29	-0.85	0.56	-0.38	-0.31	-0.54	-0.26	-0.36
Stock Option Compensation Expense	23.55	23.62	18.33	16.48	18.19	15.11	17.36	13.35
Price To Earnings Ratio	57.89	248.43	49.27	39.76	73.96	63.71	92.63	40.07
Price To Sales Ratio	14.73	12.39	5.47	5.48	13.39	12.35	19.97	8.84
Gross Margin	98.65	98.41	98.25	98.74	97.79	98.23	98.47	98.37
Operating Margin	33.70	16.12	-30.08	2.22	4.92	13.72	2.17	13.89
Net Margin	36.56	16.45	-18.92	11.83	9.32	17.80	12.90	16.71
Shares Outstanding	109.36	107.92	107.33	105.97	105.12	105.29	105.98	105.11
Market Capitalization	8,027.64	9,334.26	4,287.94	3,660.54	8,757.47	7,783.70	12,050.55	5,279.61

Balance sheet, annual

Currency USD, millions
Metric	2025FY	2024FY	2023FY	2022FY	2021FY	2020FY	2019FY	2018FY	2017FY
Cash & Short Term Investments	372.15	383.33	368.22	431.67	223.53	440.70	275.96	206.76	88.74
Short Term Receivables	63.89	58.08	56.82	46.86	29.02	26.20	19.93	17.59	28.20
Inventories	12.87	12.41	7.73	6.10	4.99	4.91	5.42	4.73	4.58
Other Current Assets	31.50	13.29	25.86	14.62	8.91	6.70	6.04	7.74	2.67
Total Current Assets	480.40	467.11	458.64	499.25	266.46	478.50	307.36	236.82	124.19
Net Property, Plant & Equipment	6.47	8.01	0.32	1.78	1.52	4.18	4.50	0.66	0.52
Total Investments and Advances	160.27	219.83	57.18	4.95	112.28	36.20	39.35	0.00	15.28
Intangible Assets	-	-	-	0.00	0.00	0.00	0.00	0.00	0.00
Deferred Tax Assets	169.58	132.22	90.61	61.47	27.45	31.60	45.68	62.66	76.70
Other Assets	21.31	14.69	14.79	15.99	16.05	21.25	15.43	11.56	3.85
Total Assets	838.03	841.85	621.52	583.43	423.76	571.73	412.31	311.69	220.54
Short Term Debt Incl. Current Port. of LT Debt	1.08	0.83	0.15	1.14	0.53	2.05	1.56	0.00	0.00
Accounts Payable	40.44	15.38	17.40	11.98	6.91	10.55	7.54	8.27	8.58
Income Tax Payable	-	0.19	1.81	0.09	0.51	-	0.47	1.54	-
Other Current Liabilities	124.56	124.57	85.14	59.28	39.59	34.89	29.27	25.77	20.99
Total Current Liabilities	166.09	140.77	104.50	72.49	47.54	47.49	38.84	35.57	29.57
Long Term Debt	5.02	6.11	0.00	0.00	0.00	0.50	1.90	0.00	0.00
Provision for Risks Charges	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Deferred Tax Liabilities	1.38	1.30	-	-	-	-	-	-	-
Other Liabilities	17.74	14.08	10.31	9.10	0.41	0.40	0.39	0.24	0.00
Total Liabilities	190.22	162.26	114.81	81.59	47.95	48.39	41.13	35.81	29.57
Non-Equity Reserves	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Preferred Stock - Carrying Value	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Common Equity	647.80	679.59	506.70	501.84	375.81	523.34	371.18	275.88	190.97
Total Shareholders Equity	647.80	679.59	506.70	501.84	375.81	523.34	371.18	275.88	190.97
Accumulated Minority Interest	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity	647.80	679.59	506.70	501.84	375.81	523.34	371.18	275.88	190.97
Total Liabilities & Stockholders Equity	838.03	841.85	621.52	583.43	423.76	571.73	412.31	311.69	220.54
Book Value Per Share	6.11	6.47	4.90	4.65	3.55	4.48	3.24	2.40	1.66
Tangible Book Value Per Share	6.11	6.47	4.90	4.65	3.55	4.48	3.24	2.40	1.66
Full-Time Employees	730	500	352	299	238	236	206	166	136
Price to Book Ratio	9.62	8.26	7.25	4.62	5.58	5.84	3.73	5.57	23.87
Return on Assets	11.70	19.10	17.51	20.11	22.60	21.55	26.02	28.34	89.27
Return on Equity	14.79	23.56	20.92	23.08	25.03	23.70	29.11	32.31	111.15
Return on Invested Capital	15.04	20.38	20.82	20.18	29.94	20.24	25.24	27.33	67.61
Quick Ratio	2.82	3.23	4.31	6.80	5.50	9.97	7.77	6.52	4.05
Current Ratio	2.89	3.32	4.39	6.89	5.60	10.07	7.91	6.66	4.20

Cash flow, annual

Currency USD, millions
Metric	TTM	2025FY	2024FY	2023FY	2022FY	2021FY	2020FY	2019FY	2018FY
Net Income	162.29	99.65	141.21	106.14	101.42	112.51	106.01	94.18	75.41
Depreciation	2.97	1.89	1.34	1.04	2.97	3.07	2.24	2.17	0.24
Other Funds (Non Cash)	99.31	79.40	50.42	41.13	43.83	48.02	34.99	27.57	22.03
Funds from Operations	248.78	143.40	152.77	118.82	114.31	167.95	157.33	140.80	111.74
Extraordinary Item	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Changes in Working Capital	-50.66	-1.41	45.52	8.22	6.02	-0.06	-5.36	-4.69	3.93
Income Taxes Payable	-	1.09	3.78	1.21	8.69	0.01	0.01	0.15	-
Cash from Operating Activities	198.11	142.00	198.29	127.04	120.32	167.89	151.97	136.12	115.67
Capital Expenditures	-3.49	-0.21	-2.17	-0.14	-0.41	-0.47	-1.24	-1.09	-0.30
Net Assets From Acquisitions	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Sale of Fixed Assets and Businesses	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Purchase or Sale of Investments	-165.04	69.97	-175.43	91.05	-113.91	136.59	-118.03	-116.74	-90.47
Purchase of Investments	-513.43	-319.61	-588.31	-328.75	-355.07	-312.81	-420.11	-299.04	-233.12
Sale Or Maturity of Investments	348.39	389.58	412.88	419.79	241.15	449.40	302.09	182.29	142.66
Other Uses	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Other Sources	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cash from Investing Activities	-168.53	69.76	-177.60	90.91	-114.33	136.13	-119.26	-117.83	-90.77
Cash Dividends Paid	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Change in Capital Stock	35.33	-147.43	-6.05	-139.62	4.38	-279.76	13.28	-22.56	-14.34
Repurchase of Common Pref Stock	-5.75	-172.91	-15.66	-145.43	0.00	-295.99	-9.95	-30.98	-23.66
Sale of Common Pref Stock	41.07	25.49	9.62	5.81	4.38	16.23	23.23	8.42	9.32
Proceedsfrom Stock Options	11.52	9.62	5.46	0.00	0.00	0.00	0.00	0.00	0.00
Issuance or Reduction of Debt, Net	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Change in Long Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Issuance of Long Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Reduction of Long Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Financing Active Other Cash Flow	-91.70	-72.94	-22.30	-9.11	-21.66	-22.84	-1.07	-6.09	0.00
Other Financing Activities Uses	-91.70	-72.94	-22.30	-9.11	-21.66	-22.84	-1.07	-6.09	0.00
Cash from Financing Activities	-56.38	-220.37	-28.35	-148.72	-17.28	-302.59	12.21	-28.64	-14.34
Exchange Rate Effect	-0.20	1.44	-0.23	-	-	-	-	-	-
Net Change in Cash	-27.00	-7.17	-7.89	69.22	-11.29	1.43	44.92	-10.36	10.56
Free Cash Flow	194.62	141.78	196.12	126.90	119.91	167.42	150.73	135.03	115.37
Preferred Dividends (Cash Flow)	-	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Free Cash Flow	72.94	29.45	29.16	28.60	19.64	14.90	21.55	10.98	14.67
Deferred Taxes & Investment Tax Credit	-	-37.54	-40.19	-29.49	-33.91	4.35	14.09	16.88	14.07

Balance sheet, quarterly

Currency USD, millions
Metric	2026Q3	2026Q2	2026Q1	2025Q4	2025Q3	2025Q2
Cash & Short Term Investments	370.70	308.20	338.18	372.15	421.68	342.23
Short Term Receivables	115.86	81.42	42.77	63.89	73.53	68.67
Inventories	11.91	13.19	12.89	12.87	12.35	12.28
Other Current Assets	29.34	32.45	27.77	31.50	33.57	19.94
Total Current Assets	527.81	435.25	421.62	480.40	541.13	443.11
Net Property, Plant & Equipment	11.46	11.99	10.37	6.47	6.87	7.31
Total Investments and Advances	292.27	236.45	177.26	160.27	102.56	172.78
Deferred Tax Assets	169.07	178.68	181.56	169.58	153.00	162.23
Other Assets	33.42	26.33	24.07	21.31	20.05	16.29
Total Assets	1,034.03	888.70	814.88	838.03	823.61	801.72
Short Term Debt Incl. Current Port. of LT Debt	2.02	1.92	1.63	1.08	1.05	1.02
Accounts Payable	21.92	14.91	33.31	40.44	34.45	23.52
Other Current Liabilities	153.73	136.97	114.25	124.56	136.77	120.12
Total Current Liabilities	177.68	153.80	149.19	166.09	172.26	144.66
Long Term Debt	6.97	7.50	8.01	5.02	5.31	5.59
Provision for Risks Charges	0.00	0.00	0.00	0.00	0.00	0.00
Deferred Tax Liabilities	-	-	-	1.38	-	-
Other Liabilities	15.64	21.62	19.70	17.74	14.13	15.68
Total Liabilities	200.29	182.93	176.89	190.22	191.71	165.93
Non-Equity Reserves	0.00	0.00	0.00	0.00	0.00	0.00
Preferred Stock - Carrying Value	0.00	0.00	0.00	0.00	0.00	0.00
Common Equity	833.74	705.78	637.99	647.80	631.90	635.79
Total Shareholders Equity	833.74	705.78	637.99	647.80	631.90	635.79
Accumulated Minority Interest	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity	833.74	705.78	637.99	647.80	631.90	635.79
Total Liabilities & Stockholders Equity	1,034.03	888.70	814.88	838.03	823.61	801.72
Book Value Per Share	7.62	6.54	5.94	6.11	6.01	6.04
Tangible Book Value Per Share	7.62	6.54	5.94	6.11	6.01	6.04
Full-Time Employees	-	-	-	730	-	-
Price to Book Ratio	9.62	14.63	6.59	5.79	13.76	11.38
Return on Assets	17.15	6.41	5.62	11.70	13.02	17.41
Return on Equity	21.74	8.08	7.06	14.79	16.47	21.42
Return on Invested Capital	14.81	5.91	-4.83	3.66	3.04	5.40
Quick Ratio	2.90	2.74	2.74	2.82	3.07	2.98
Current Ratio	2.97	2.83	2.83	2.89	3.14	3.06

Cash flow, quarterly

Currency USD, millions
Metric	2026Q3	2026Q2	2026Q1	2025Q4	2025Q3	2025Q2
Net Income	126.78	42.99	-31.76	24.29	19.67	35.15
Depreciation	1.03	0.86	0.60	0.48	0.48	0.47
Other Funds (Non Cash)	28.72	28.71	22.21	19.68	21.87	17.71
Funds from Operations	166.14	75.44	-22.07	29.26	51.13	35.56
Extraordinary Item	0.00	0.00	0.00	0.00	0.00	0.00
Changes in Working Capital	-23.25	-41.90	5.29	9.19	3.35	8.37
Income Taxes Payable	-	-	-	1.04	-1.54	1.42
Cash from Operating Activities	142.89	33.54	-16.77	38.45	54.48	43.94
Capital Expenditures	-0.71	-2.53	-0.20	-0.05	0.00	-0.06
Net Assets From Acquisitions	0.00	0.00	0.00	0.00	0.00	0.00
Sale of Fixed Assets and Businesses	0.00	0.00	0.00	0.00	0.00	0.00
Purchase or Sale of Investments	-131.28	-26.71	4.74	-11.79	14.64	70.18
Purchase of Investments	-228.32	-88.95	-52.33	-143.83	-37.35	-23.27
Sale Or Maturity of Investments	97.04	62.24	57.07	132.04	52.00	93.46
Other Uses	0.00	0.00	0.00	0.00	0.00	0.00
Other Sources	0.00	0.00	0.00	0.00	0.00	0.00
Cash from Investing Activities	-131.99	-29.24	4.54	-11.84	14.64	70.13
Cash Dividends Paid	0.00	0.00	0.00	0.00	0.00	0.00
Preferred Dividends (Cash Flow)	0.00	0.00	0.00	0.00	0.00	0.00
Change in Capital Stock	14.06	9.42	6.52	5.32	-38.26	-90.51
Repurchase of Common Pref Stock	-5.75	0.00	0.00	0.00	-42.46	-103.02
Sale of Common Pref Stock	19.81	9.42	6.52	5.32	4.20	12.51
Proceedsfrom Stock Options	2.86	3.66	2.54	2.46	2.17	3.27
Issuance or Reduction of Debt, Net	0.00	0.00	0.00	0.00	0.00	0.00
Change in Long Term Debt	0.00	0.00	0.00	0.00	0.00	0.00
Issuance of Long Term Debt	0.00	0.00	0.00	0.00	0.00	0.00
Reduction of Long Term Debt	0.00	0.00	0.00	0.00	0.00	0.00
Net Financing Active Other Cash Flow	-37.95	-11.46	-5.76	-36.54	-8.15	-12.43
Other Financing Activities Uses	-37.95	-11.46	-5.76	-36.54	-8.15	-12.43
Cash from Financing Activities	-23.89	-2.04	0.76	-31.22	-46.41	-102.93
Exchange Rate Effect	0.08	0.04	-0.29	-0.03	-0.32	-
Net Change in Cash	-12.90	2.30	-11.76	-4.64	22.39	12.93
Free Cash Flow	142.18	31.02	-16.97	38.40	54.48	43.88
Price to Free Cash Flow	72.94	96.27	35.14	29.42	61.06	49.06

Revenue breakdown

Pharmaceutical Preparations	2024: 675.04M 2025: 761.41M
United States	2024: 675.04M 2025: 761.41M

Short interest

shares short against float, oldest to newest

Settlement	Of float	Shares short	Float	Avg volume
2026-10-30	9.41%	9.1M	97.0M	1.18M
2026-10-15	8.97%	8.6M	95.8M	1.24M
2026-09-30	8.92%	8.5M	95.8M	1.31M
2026-09-15	9.76%	9.4M	95.8M	1.08M
2026-08-31	9.81%	9.4M	95.8M	1.08M
2026-08-14	10.12%	9.7M	95.8M	1.12M
2026-07-31	10.30%	9.8M	95.4M	1.22M
2026-07-15	9.97%	9.4M	94.7M	1.10M
2026-06-30	9.13%	8.6M	94.7M	1.12M
2026-06-15	9.05%	8.6M	94.7M	1.40M
2026-05-29	9.29%	8.8M	94.7M	1.44M
2026-05-15	9.94%	9.3M	93.8M	1.69M
2026-04-30	11.32%	10.7M	94.6M	1.65M
2026-04-15	12.10%	11.3M	93.7M	1.96M
2026-03-31	13.28%	12.4M	93.7M	2.19M
2026-03-13	13.90%	13.0M	93.7M	2.26M
2026-02-27	13.30%	12.5M	93.7M	2.18M
2026-02-13	10.71%	10.0M	93.7M	1.85M
2026-01-30	10.00%	9.3M	92.8M	1.78M
2026-01-15	8.81%	8.2M	92.9M	1.45M

Option chain

expiry 2026-11-20

Type	Strike	Bid	Ask	Last	IV	Open int	Volume	Delta	Theta	Vega
call	17.50	54.90	59.10	63.10	7.902	1.00	0.00	0.987	-0.111	0.004
call	20.00	52.60	56.60	60.60	7.188	1.00	0.00	0.986	-0.111	0.004
call	22.50	50.10	54.10	58.10	6.576	1.00	0.00	0.980	-0.144	0.006
call	25.00	47.60	51.50	54.00	6.041	4.00	0.00	0.978	-0.144	0.006
call	27.50	45.00	49.00	0.00	5.565	0.00	0.00	0.976	-0.143	0.007
call	30.00	42.50	46.50	0.00	5.136	0.00	0.00	0.974	-0.142	0.007
call	32.50	40.00	44.00	46.40	4.746	5.00	0.00	0.971	-0.141	0.008
call	35.00	37.50	41.50	44.00	4.388	6.00	0.00	0.969	-0.140	0.008
call	37.50	35.00	39.00	0.00	4.056	0.00	0.00	0.966	-0.138	0.009
call	40.00	32.50	36.50	40.70	3.746	2.00	0.00	0.963	-0.136	0.009
call	42.50	30.00	34.00	33.70	3.456	3.00	0.00	0.959	-0.134	0.010
call	45.00	27.60	31.50	51.20	3.181	6.00	0.00	0.956	-0.132	0.011
call	47.50	25.10	29.00	16.15	2.921	5.00	0.00	0.951	-0.129	0.012
call	50.00	22.60	26.60	26.85	2.672	72.00	0.00	0.947	-0.127	0.013
call	52.50	20.20	24.10	21.83	2.473	0.00	0.00	0.941	-0.123	0.014
call	55.00	18.20	21.60	63.00	2.241	134	0.00	0.934	-0.120	0.015
call	57.50	15.60	18.80	60.20	1.874	7.00	0.00	0.926	-0.116	0.016
call	60.00	13.20	16.50	21.50	1.731	12.00	0.00	0.916	-0.111	0.018
call	62.50	10.90	14.00	24.40	1.520	2.00	0.00	0.844	-0.194	0.028
call	65.00	8.80	11.80	11.54	1.419	14.00	0.00	0.819	-0.180	0.030
call	67.50	6.80	9.60	0.00	1.257	0.00	0.00	0.784	-0.169	0.034
call	70.00	4.90	7.70	39.44	1.189	23.00	0.00	0.694	-0.199	0.041
call	72.50	3.50	4.70	4.10	0.828	7.00	0.00	0.600	-0.199	0.045
call	75.00	2.20	3.10	2.88	0.749	304	1.00	0.484	-0.188	0.046
call	77.50	1.45	2.10	1.49	0.732	174	0.00	0.385	-0.192	0.044
call	80.00	0.85	1.30	1.65	0.711	44.00	2.00	0.279	-0.162	0.039
call	82.50	0.00	2.60	0.66	0.822	43.00	0.00	0.243	-0.170	0.037
call	85.00	0.00	2.35	1.66	0.982	1,002	0.00	0.215	-0.188	0.034
call	87.50	0.00	2.25	0.47	1.078	60.00	0.00	0.200	-0.199	0.033
call	90.00	0.00	0.60	0.58	0.939	401	0.00	0.118	-0.123	0.023
call	92.50	0.00	1.75	0.30	1.048	20.00	0.00	0.109	-0.129	0.022
call	95.00	0.00	2.15	0.17	1.126	149	0.00	0.103	-0.133	0.021
call	97.50	0.00	1.35	1.60	1.225	38.00	0.00	0.097	-0.137	0.020
call	100	0.00	2.15	0.10	1.308	548	0.00	0.092	-0.141	0.019
call	105	0.00	1.10	0.75	1.464	60.00	0.00	0.084	-0.148	0.018
call	110	0.00	1.75	0.05	1.608	198	0.00	0.078	-0.154	0.017
call	115	0.00	1.00	1.00	1.735	329	0.00	0.073	-0.158	0.016
call	120	0.00	2.15	1.13	1.873	588	0.00	0.069	-0.164	0.016
call	125	0.00	2.15	0.05	2.007	88.00	0.00	0.066	-0.168	0.015
call	130	0.00	2.15	0.05	2.102	124	0.00	0.064	-0.171	0.015
call	135	0.00	2.15	0.88	2.220	191	0.00	0.061	-0.175	0.014
call	140	0.00	2.15	0.05	2.313	488	0.00	0.059	-0.178	0.014
call	145	0.00	2.15	0.10	2.409	102	0.00	0.057	-0.181	0.013
call	150	0.00	1.95	0.85	2.485	25.00	0.00	0.056	-0.183	0.013
call	155	0.00	1.95	0.90	2.587	57.00	0.00	0.054	-0.186	0.013
call	160	0.00	1.95	0.45	2.663	45.00	0.00	0.053	-0.188	0.013
call	165	0.00	2.15	0.00	2.748	0.00	0.00	0.052	-0.190	0.012
call	170	0.00	2.15	0.40	2.832	104	0.00	0.051	-0.193	0.012
call	175	0.00	2.15	1.35	2.912	5.00	0.00	0.050	-0.195	0.012
call	180	0.00	0.50	1.10	2.074	5.00	0.00	0.007	-0.024	0.002
put	17.50	0.00	2.15	0.00	5.042	0.00	0.00	-0.013	-0.109	0.004
put	20.00	0.00	0.35	0.00	4.353	0.00	0.00	-0.015	-0.099	0.004
put	22.50	0.00	2.15	0.00	4.493	0.00	0.00	-0.020	-0.142	0.006
put	25.00	0.00	2.15	0.78	4.122	1.00	0.00	-0.022	-0.141	0.006
put	27.50	0.00	2.15	0.86	3.790	1.00	0.00	-0.024	-0.140	0.007
put	30.00	0.00	2.15	0.00	3.498	0.00	0.00	-0.026	-0.139	0.007
put	32.50	0.00	2.15	0.00	3.211	0.00	0.00	-0.029	-0.137	0.008
put	35.00	0.00	2.15	0.00	2.962	0.00	0.00	-0.031	-0.136	0.008
put	37.50	0.00	2.15	3.87	2.714	1.00	0.00	-0.034	-0.134	0.009
put	40.00	0.00	0.75	0.00	2.489	0.00	0.00	-0.037	-0.129	0.009
put	42.50	0.00	0.75	1.20	2.295	3.00	0.00	-0.040	-0.128	0.010
put	45.00	0.00	1.75	1.60	2.084	1.00	0.00	-0.044	-0.125	0.011
put	47.50	0.00	0.50	0.40	2.376	5.00	0.00	-0.095	-0.244	0.020
put	50.00	0.00	0.95	0.00	1.553	0.00	0.00	-0.038	-0.083	0.010
put	52.50	0.00	0.75	0.00	1.395	0.00	0.00	-0.042	-0.081	0.010
put	55.00	0.00	1.25	0.00	1.370	0.00	0.00	-0.066	-0.114	0.015
put	57.50	0.00	2.25	0.00	1.228	0.00	0.00	-0.072	-0.110	0.016
put	60.00	0.00	0.50	0.20	1.049	337	80.00	-0.084	-0.104	0.018
put	62.50	0.00	2.40	1.05	1.234	2.00	0.00	-0.152	-0.189	0.028
put	65.00	0.00	2.60	0.88	1.051	38.00	0.00	-0.175	-0.175	0.030
put	67.50	0.45	1.25	0.75	0.832	101	57.00	-0.218	-0.162	0.034
put	70.00	0.90	1.70	1.35	0.765	89.00	27.00	-0.302	-0.190	0.040
put	72.50	1.70	2.60	2.15	0.752	55.00	2.00	-0.395	-0.191	0.045
put	75.00	2.75	3.50	3.40	0.678	57.00	0.00	-0.510	-0.180	0.046
put	77.50	4.20	5.70	5.30	0.828	19.00	0.00	-0.615	-0.183	0.044
put	80.00	4.90	7.70	9.00	0.895	187	0.00	-0.721	-0.153	0.039
put	82.50	6.90	9.80	10.00	0.981	7.00	0.00	-0.760	-0.163	0.036
put	85.00	9.20	12.30	11.09	1.084	88.00	0.00	-0.786	-0.180	0.034
put	87.50	11.30	14.90	14.50	1.240	21.00	0.00	-0.803	-0.192	0.032
put	90.00	13.80	17.30	17.00	1.331	422	0.00	-0.883	-0.114	0.023
put	92.50	16.20	19.80	19.87	1.443	4.00	0.00	-0.892	-0.119	0.022
put	95.00	18.90	22.20	22.10	1.518	73.00	0.00	-0.898	-0.123	0.021
put	97.50	21.40	24.80	13.00	1.638	13.00	0.00	-0.904	-0.127	0.020
put	100	23.80	27.20	23.14	1.714	309	0.00	-0.909	-0.131	0.019
put	105	28.70	32.30	31.75	1.930	24.00	0.00	-0.916	-0.137	0.018
put	110	34.00	37.00	36.88	1.965	335	0.00	-0.922	-0.142	0.017
put	115	38.50	42.50	28.90	2.328	0.00	0.00	-0.927	-0.147	0.016
put	120	43.50	47.50	27.40	2.476	3.00	0.00	-0.931	-0.151	0.015
put	125	48.50	52.50	19.16	2.615	4.00	0.00	-0.934	-0.154	0.015
put	130	53.50	57.30	53.90	2.667	0.00	0.00	-0.937	-0.157	0.014
put	135	58.50	62.50	58.90	2.871	0.00	0.00	-0.939	-0.160	0.014
put	140	63.50	67.50	0.00	2.990	0.00	0.00	-0.941	-0.163	0.014
put	145	68.50	72.30	0.00	3.018	0.00	0.00	-0.943	-0.165	0.013
put	150	73.50	77.50	0.00	3.210	0.00	0.00	-0.944	-0.167	0.013
put	155	78.50	82.30	0.00	3.226	0.00	0.00	-0.946	-0.169	0.013
put	160	83.50	87.30	0.00	3.324	0.00	0.00	-0.947	-0.171	0.013
put	165	88.50	92.50	0.00	3.507	0.00	0.00	-0.948	-0.173	0.012
put	170	93.50	97.50	0.00	3.598	0.00	0.00	-0.949	-0.175	0.012
put	175	98.50	102.5	0.00	3.686	0.00	0.00	-0.950	-0.176	0.012
put	180	103.5	107.5	0.00	3.770	0.00	0.00	-0.957	-0.152	0.011

Latest SEC filings

Filed	Form	Description	Period	Link
2026-11-10	144	Filing for proposed sale of securities under Rule 144.		SEC
2026-11-04	4	Statement of changes in beneficial ownership of securities	2026-11-02	SEC
2026-11-04	4	Statement of changes in beneficial ownership of securities	2026-11-02	SEC
2026-11-03	10-Q	Quarterly report pursuant to Section 13 or 15(d)	2026-09-30	SEC
2026-11-03	8-K	Current report	2026-11-03	SEC
2026-10-27	SCHEDULE 13G/A			SEC
2026-10-16	4	Statement of changes in beneficial ownership of securities	2026-10-15	SEC
2026-10-05	4	Statement of changes in beneficial ownership of securities	2026-10-02	SEC
2026-10-05	4	Statement of changes in beneficial ownership of securities	2026-10-01	SEC
2026-10-05	4	Statement of changes in beneficial ownership of securities	2026-10-01	SEC
2026-10-05	4	Statement of changes in beneficial ownership of securities	2026-10-01	SEC
2026-10-05	3	Initial statement of beneficial ownership of securities	2026-10-01	SEC
2026-10-01	144	Filing for proposed sale of securities under Rule 144.		SEC
2026-09-28	4	Statement of changes in beneficial ownership of securities	2026-09-24	SEC
2026-09-23	8-K	Current report	2026-09-22	SEC
2026-09-18	4	Statement of changes in beneficial ownership of securities	2026-09-16	SEC
2026-09-18	4	Statement of changes in beneficial ownership of securities	2026-09-17	SEC
2026-09-16	4	Statement of changes in beneficial ownership of securities	2026-09-14	SEC
2026-09-16	4	Statement of changes in beneficial ownership of securities	2026-09-15	SEC
2026-09-15	144	Filing for proposed sale of securities under Rule 144.		SEC
2026-09-14	144	Filing for proposed sale of securities under Rule 144.		SEC
2026-09-03	4	Statement of changes in beneficial ownership of securities	2026-09-01	SEC
2026-09-03	4	Statement of changes in beneficial ownership of securities	2026-09-01	SEC
2026-09-03	4	Statement of changes in beneficial ownership of securities	2026-09-01	SEC
2026-09-03	4	Statement of changes in beneficial ownership of securities	2026-09-01	SEC
2026-09-03	4	Statement of changes in beneficial ownership of securities	2026-09-01	SEC
2026-09-03	4	Statement of changes in beneficial ownership of securities	2026-09-01	SEC
2026-09-03	3	Initial statement of beneficial ownership of securities	2026-09-01	SEC
2026-09-02	144	Filing for proposed sale of securities under Rule 144.		SEC
2026-08-28	4	Statement of changes in beneficial ownership of securities	2026-08-26	SEC

Insider activity by month

Month	Bought	Buys	Sold	Sells
2026-11	0	0	2.72M	3
2026-10	0	0	6.18M	6
2026-09	0	0	11.59M	5
2026-08	0	0	27.00M	11
2026-07	0	0	17.64M	5
2026-06	0	0	12.63M	7
2026-05	0	0	8.28M	4
2026-04	0	0	819.40K	1
2026-03	3.31M	1	2.03M	3
2026-02	0	0	817.33K	1
2026-01	0	0	703.66K	1
2025-12	0	0	6.78M	4
2025-11	0	0	6.70M	6

Institutional holders

Manager	% owned
BlackRock, Inc.	11.58%
INGALLS & SNYDER LLC	7.39%
RENAISSANCE TECHNOLOGIES LLC	4.90%
VANGUARD PORTFOLIO MANAGEMENT LLC	4.70%
VANGUARD CAPITAL MANAGEMENT LLC	3.89%
Parallel Advisors, LLC	3.61%
FMR LLC	3.23%
STATE STREET CORP	3.05%
AQR CAPITAL MANAGEMENT LLC	2.41%
GEODE CAPITAL MANAGEMENT, LLC	2.16%

Funds

Fund	% owned
iShares Core S&P Small-Cap ETF	5.36%
VANGUARD TOTAL STOCK MARKET INDEX FUND	2.70%
VANGUARD SMALL-CAP INDEX FUND	1.95%
First Trust NYSE Arca Biotechnology Index Fund	1.69%
Fidelity Contrafund	1.23%
VANGUARD SMALL-CAP GROWTH INDEX FUND	1.12%
VANGUARD EXTENDED MARKET INDEX FUND	1.02%
State Street(R) SPDR(R) Portfolio S&P 600(TM) Small Cap ETF	0.82%
iShares S&P Small-Cap 600 Growth ETF	0.80%
VANGUARD TAX-MANAGED SMALL-CAP FUND	0.57%

OakChart. CORT. Cached 15 minutes.